Key Highlights

● Third quarter sales were about $13 billion, up 14.5% as reported and 7% comparable.

● Adjusted diluted earnings were $1.42 per share, while reported earnings fell to 53 cents.

● Legal settlements of roughly $670 million and amortization weighed on reported earnings.

● Abbott narrowed full-year adjusted earnings guidance to $5.50 to $5.55 per share.

Abbott Laboratories (NYSE:ABT), the diversified medical technology company and a long-standing constituent of the S&P 500, released third quarter results on Wednesday, October 21. According to the earnings release furnished to the Securities and Exchange Commission, net sales were about $13 billion, a gain of roughly 14.5% on a reported basis and 7% on a comparable basis that strips out currency effects.

The headline contrast in the release is between two measures of earnings. Adjusted diluted earnings per share rose to $1.42, while reported diluted earnings per share fell to 53 cents. The difference comes from charges the company classifies as specified items, which this quarter included large legal settlements and the amortization that follows an acquisition.

What Were the Headline Numbers in the Abbott Third Quarter Release?

Abbott reported net sales of about $13 billion for the third quarter, compared with roughly $11.4 billion in the year-earlier period. The reported increase was about 14.5%, and the comparable increase, which excludes the effect of foreign exchange, was 7%.

The gap between reported and comparable growth is explained mostly by the acquisition of Exact Sciences, a cancer diagnostics company, which closed on March 23 and added a new layer of sales that was not in the prior-year quarter. Currency movements also contributed to the difference.

On earnings, the company reported net earnings of about $920 million on a reported basis and about $2.5 billion when specified items are excluded. Adjusted diluted earnings per share were $1.42, a gain of about 9% from $1.30 a year earlier.

Chairman and chief executive Robert Ford said in the release that the company delivered strong results reflecting balanced growth across its portfolio.

Why Did Abbott's Reported Diluted Earnings Fall to 53 Cents Per Share?

Reported diluted earnings per share were 53 cents, down from 94 cents, a decline of about 44%. The company attributes the difference from adjusted earnings to specified items that reduced per-share results by about 89 cents, equal to after-tax charges of roughly $1.6 billion.

The largest identifiable pieces were amortization of intangible assets of about $841 million and legal settlements of about $670 million. The settlements relate to the Gill case and to claims about necrotizing enterocolitis, a serious intestinal condition in premature infants that has been the subject of litigation involving infant formula makers.

Tax items also played a role, including roughly $35 million of net expense tied to prior-year tax positions and about $100 million in adjustments connected to an earlier non-cash deferred tax benefit.

Companies exclude such items from adjusted results because they view them as unrelated to ongoing operations. Critics sometimes question that approach when charges recur, and the legal costs in particular are a reminder that product liability matters can carry large and uncertain financial consequences.

How Did Abbott's Medical Devices and Diabetes Care Units Perform?

Medical Devices sales were about $5.8 billion, up almost 7% as reported and nearly 8% on a comparable basis. Electrophysiology, the business that treats abnormal heart rhythms, grew about 15% as reported, and Rhythm Management rose almost 10%.

Diabetes Care, which sits within the devices group, generated about $2.2 billion in sales, up roughly 6% as reported and nearly 7% comparable. Continuous glucose monitor sales rose about 7% as reported. The category includes the Libre family of sensors, and the company noted an August approval from the Food and Drug Administration for Libre Duo, a sensor that measures both glucose and ketones.

Other device milestones listed in the release include a CE Mark in August for the Amulet 360 left atrial appendage occluder and a September FDA approval for the TactiFlex Duo ablation catheter. Such approvals broaden the product lineup, though revenue contributions typically build gradually after launch.

Continuous glucose monitoring is a competitive field in which Abbott and a small number of rivals fight for share among both insulin users and, increasingly, people with type two diabetes who do not use insulin. Growth in the high single digits for the Abbott franchise is steady, though not as rapid as some past periods.

What Did the Exact Sciences Acquisition Do to Abbott's Diagnostics Sales?

Diagnostics sales were about $3.3 billion, up almost 47% as reported but only about 6% on a comparable basis. The difference is the contribution of Exact Sciences, which the company acquired on March 23.

Within the segment, cancer diagnostics reached about $968 million, a comparable gain of nearly 14%. That line captures screening and testing products such as those Exact Sciences built around early detection of colorectal and other cancers.

In September, the company launched SimpleScreen CRC, a blood-based colorectal cancer screening test. Blood-based screening is an emerging category in which convenience is the main appeal for people who avoid colonoscopies or stool-based tests, though performance characteristics, coverage decisions and guideline endorsements will shape adoption.

The acquisition also explains the heavy amortization charge noted above. When a company acquires another, it records identifiable intangible assets, such as technology and customer relationships, and then writes them down over time. That reduces reported earnings without any cash leaving the business in the same period, which is why the adjusted measure excludes it. Integration cost and cultural fit are the other practical challenges that large health care combinations usually face.

How Are Abbott's Nutrition and Established Pharmaceuticals Businesses Doing?

Nutrition sales were about $2.3 billion, up roughly 5% both as reported and on a comparable basis. Pediatric nutrition grew almost 9% as reported, and the company pointed to the August launch of Similac 360 Total Care made with whole milk.

Nutrition is also the part of the company at the center of the necrotizing enterocolitis litigation noted earlier. The legal settlements recorded this quarter relate to that matter, and the company has defended its products in court while also resolving certain claims. Further legal developments remain possible, and the financial effects are difficult to estimate from outside the company.

Established Pharmaceuticals, which markets branded generics in markets outside the United States, produced sales of about $1.6 billion, up almost 7% as reported and over 8% on a comparable basis. That unit often benefits from rising demand in emerging markets and from steady price realization, though it is sensitive to currency swings.

Taken together, the four lines of business each grew in the third quarter, and none declined on a comparable basis. The level of growth varied, with devices and established pharmaceuticals near 8% and nutrition and diagnostics closer to 5% and 6%.

What Full-Year Guidance Did Abbott Reaffirm, and What Does the Fourth Quarter Imply?

The company reaffirmed the midpoint of its full-year adjusted earnings guidance while narrowing the range to $5.50 to $5.55 per share. It expects comparable sales growth of about 6% for the full year.

For the fourth quarter, Abbott guided adjusted earnings of $1.62 to $1.67 per share. That range is above the $1.42 reported for the third quarter, reflecting normal seasonal patterns and the continuing contribution of the diagnostics acquisition.

Guidance is a statement of management expectation, not a result, and it can change if conditions change. In health care device businesses, the main swing factors include currency, procedure volumes at hospitals, reimbursement decisions, and supply costs. Tariff developments can also affect cost structures for companies that manufacture and distribute across borders.

The decision to reaffirm and not raise the guidance is consistent with a company that is absorbing acquisition costs and legal charges while still growing sales. Market participants often read narrowing of a range as a modest signal of confidence, because it removes the low end of the previous band.

What Is the Abbott Dividend Record, and How Much Cash Is Being Distributed?

Abbott also declared its regular quarterly dividend of 63 cents per share, the 411th consecutive quarterly dividend in the company's history, according to the release. It is payable on November 16 to stock owners of record on October 15.

The company has paid dividends without interruption for more than a century, a record that places it among the longest-running dividend payers in American corporate history. Abbott is also known for increasing the payout in many consecutive years, which keeps it on the lists that dividend-focused market participants track.

A dividend of that kind is paid from cash flow and not directly from reported earnings, and a quarter with large legal settlements and acquisition amortization does not necessarily change the cash picture in the same way. Settlements themselves, however, are paid in cash, and the acquisition added to debt and to the interest burden, so the balance sheet is a legitimate item to follow.

How Does the Abbott Quarter Fit Into the Broader Medical Technology Season?

Medical technology companies have been reporting steady procedure demand this season, with hospitals continuing to work through backlogs of elective treatments and with new product categories such as pulsed field ablation and sensor-based glucose monitoring gaining ground. Abbott's electrophysiology growth near 15% is consistent with that broad theme.

At the same time, the sector faces uncertainties. Hospital budgets are under pressure from labor costs, federal policymakers continue to debate reimbursement, and competitive launches in cardiac and diabetes devices can shift share quickly. Diagnostics markets also face pricing pressure and changes in testing demand after the pandemic period.

Abbott's mix is unusual among large peers because it blends devices, diagnostics, nutrition and branded generics. That breadth smooths results in some periods and complicates comparison in others, since each of the four segments follows a different cycle and faces different regulators.

The third quarter shows comparable growth of 7% and an adjusted earnings gain of about 9%, with a reported result that was held down by one-time legal and accounting charges.

What Should Readers Follow Next at Abbott Beyond This Earnings Report?

The next scheduled event is the fourth quarter and full-year report, which the company normally issues in January. By then, the first full year of Exact Sciences results will be nearly complete, and the integration of that business will be easier to evaluate.

Other items worth tracking include the uptake of the dual glucose-ketone sensor, regulatory progress for ablation and heart devices, adoption of the blood-based colorectal screening test, and any additional legal developments around infant formula. Each can influence sentiment independently of the quarterly sales trend.

Adjusted measures are not defined by generally accepted accounting principles, and the company's choices about what to exclude are disclosed in the filing.